RxDoctor Payments DataLook up a doctor →

Anil Verma, MD

Cardiovascular Disease · Cincinnati, OHNPI 1669521365

Payments from drug & device makers

$195,403in general payments, 2019–2025

Across 747 payments — averaging $261.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$90K
  • Penumbra, Inc.$46K
  • Abbott$21K
  • Boston Scientific$14K
  • EKOS Corporation$6K
  • Imperative Care, Inc$4K
  • plus $13K from 42 others

What the payments were for

  • Consulting fees$1,0003%
  • Speaking & faculty fees$4,80014%
  • Travel & lodging$1,8416%
  • Food & beverage$25,65277%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$195,403 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$165,310
Medicare patients
470
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$181,723
XareltoRivaroxaban49$70,205
EntrestoSacubitril/Valsartan45$63,996
FarxigaDapagliflozin Propanediol31$35,831
BrilintaTicagrelor55$31,809
JardianceEmpagliflozin28$27,391
ClopidogrelClopidogrel Bisulfate502$3,485
Ranolazine ErRanolazine18$2,514
Atorvastatin Calcium295$1,866
Metoprolol Succinate173$1,573
Torsemide87$1,379
Amiodarone Hcl42$1,143
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$934
Rosuvastatin Calcium90$762
Carvedilol98$679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$221$181,723165 claims
Johnson & JohnsonXarelto$1,095$70,20549 claims
AstraZenecaFarxiga, Brilinta$46$67,64086 claims
NovartisEntresto$1,263$63,99645 claims
Boehringer IngelheimJardiance$154$27,39128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →